Cargando…

Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern

SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Low, Jia Ming, Gu, Yue, Ng, Melissa Shu Feng, Wang, Liang Wei, Amin, Zubair, Zhong, Youjia, MacAry, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880232/ https://www.ncbi.nlm.nih.gov/pubmed/35214683 http://dx.doi.org/10.3390/vaccines10020225

Ejemplares similares

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2
por: Speer, Claudius, et al.
Publicado: (2021)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
por: Kustin, Talia, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Immune and pathophysiologic profiling of antenatal coronavirus disease 2019 in the GIFT cohort: A Singaporean case-control study
por: Gu, Yue, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Epigenomic landscape exhibits interferon signaling suppression in the patient of myocarditis after BNT162b2 vaccination
por: Kim, Hyeonhui, et al.
Publicado: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
por: Jahrsdörfer, Bernd, et al.
Publicado: (2021)

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination
por: Bonura, Floriana, et al.
Publicado: (2022)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
por: Rosenberg-Friedman, Michal, et al.
Publicado: (2021)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
por: Trabace, Luigia, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
por: Valleriani, Fabrizia, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
por: Bartsch, Yannic C., et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
por: Gray, Glenda, et al.
Publicado: (2022)

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
por: Bauswein, Markus, et al.
Publicado: (2022)

Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022)

Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
por: Jalkanen, Pinja, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
por: Habib, Mhd Baraa, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lcu2n02ge9auiat8oa42lbjrn1